CJC-1295 (with DAC)

Estimated Market Price

$27 – $75

Estimated for 2–5 mg vial · Based on verified supplier pricing

Long-acting GHRH analog with Drug Affinity Complex for sustained GH elevation. Extended 6-8 day half-life for convenient, consistent growth hormone optimization.

How it works

Works like CJC-1295 (no DAC) by stimulating pituitary GH release, but attaches to a blood protein called albumin to stay active for about 8 days. This produces a steady, elevated GH level rather than natural pulses.

Growth Hormone

Performance

What to Expect

Week 1–2 Sustained GH elevation begins; improved sleep and recovery. Better sleep; feeling more recovered in the mornings.

Week 3–4 Steady-state albumin binding achieved; consistent GH output. Consistent energy; recovery between gym sessions improving.

Week 5–8 Body composition improving; fat loss and lean mass gains. Visible body composition changes; leaner and firmer.

Week 9–12 Full protocol benefits realized; labs recommended for assessment. Looking and feeling noticeably better overall.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier

LarnaLabs Verified Supplier · larnalabs.com

NXPeptides Verified Supplier · nxpeptides.com

BioSynth Verified Custom Batch Supplier · biosynth.com

Peptide Sciences Unavailable · peptidesciences.com

Protocol & Dosage

Typical Dosage 1–2 mg SC, 1–2 times per week

Administration Subcutaneous injection

Schedule 1–2x per week (long-acting)

Protocol Duration 8–12 weeks on, then off 30 days

Half-Life 6–8 days (due to albumin binding)

Side Effects & Safety

Tolerability Profile Moderate

Notable side effects likely; manageable with proper awareness

Common Side Effects

Injection site reactionmost users
Water retention and bloatingmost users
Mild flushingsome users
Vivid dreamssome users

Less Common

Joint stiffnessoccasional
Headacheoccasional
Tingling or numbnessoccasional
Elevated IGF-1 beyond target rangeoccasional

Rare / Serious

Persistent edemarare
Elevated fasting blood sugarrare

Discontinue If

Persistent edema or swelling (face, hands, feet)
Carpal tunnel symptoms (hand numbness, weakness)
Signs of elevated blood sugar

Contraindications

Active cancer or tumors
Diabetic retinopathy
Pregnancy or breastfeeding

Data note: Long-acting albumin-bound version creates sustained (non-pulsatile) GH elevation for ~8 days. Higher side effect profile than non-DAC version due to continuous GH stimulation.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about CJC-1295 (with DAC)

How to Apply

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

Sanitize

Wipe tops of both vials with alcohol swabs

Draw

Pull 1–2 mL of BAC water into syringe

Add Water

Release water slowly along vial wall, not directly on powder

Swirl

Roll between palms until dissolved. Never shake.

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for CJC-1295 (with DAC)

Also Known As CJC-1295 with DAC, Drug Affinity Complex CJC-1295

Classification GHRH Analog · Long-Acting Growth Hormone Releasing

Sequence Modified GHRH(1-29) + Drug Affinity Complex (Maleimidopropionic acid-lysine)

Molecular Formula C₁₆₅H₂₇₁N₄₇O₄₆

Molecular Weight 3,647.28 Da

CAS Number 863288-34-0

Half-Life 6–8 days (due to albumin binding)

Origin Synthetic GHRH analog with covalent albumin-binding moiety

Administration Subcutaneous injection

Status Research compound

Mechanism of Action Works like CJC-1295 (no DAC) by stimulating pituitary GH release, but attaches to a blood protein called albumin to stay active for about 8 days. This produces a steady, elevated GH level rather than natural pulses.

Research Overview CJC-1295 with Drug Affinity Complex (DAC) represents an innovative pharmacokinetic engineering approach to creating a long-acting growth hormone-releasing hormone analog. Developed by ConjuChem Biotechnologies in Montreal, Canada, the compound builds upon the same modified GHRH(1-29) backbone as Mod GRF 1-29 but adds a crucial modification - a reactive maleimidopropionic acid-lysine linker (the Drug Affinity Complex) that covalently and irreversibly binds to serum albumin in vivo through a thiol-maleimide reaction with albumin's cysteine-34 residue. This albumin conjugation exploits the naturally long circulatory half-life of human serum albumin (approximately 19 days) to dramatically extend the peptide's pharmacokinetic profile, achieving an effective half-life of approximately 8 days - a roughly 15-fold improvement over the non-DAC version. The Phase I/II clinical study published by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism demonstrated that a single subcutaneous injection of CJC-1295 DAC produced sustained elevation of growth hormone and IGF-1 levels for 6-14 days, with a mean IGF-1 increase of 1.5 to 3-fold above baseline maintained for up to two weeks. However, this sustained, non-pulsatile GH elevation represents a fundamentally different pharmacological profile than the pulsatile stimulation produced by the non-DAC version, and there is ongoing scientific debate about whether continuous versus pulsatile GH elevation produces optimal physiological outcomes. Continuous GH stimulation may lead to GH receptor downregulation over time and potentially blunted tissue responses, whereas pulsatile secretion is the body's natural pattern and may better maintain receptor sensitivity. ConjuChem's clinical development program was ultimately discontinued for commercial rather than safety reasons, and the DAC technology platform has since been applied to other therapeutic peptides.

Citations

Published findings on CJC-1295 (with DAC) from peer-reviewed journals.